We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




MRI Innovation That Makes Cancerous Tissue Glow Could Be a Game-Changer for Cancer Imaging

By MedImaging International staff writers
Posted on 22 Mar 2022
Image: MRI innovation makes cancerous tissue light up and easier to see (Photo courtesy of Pexels)
Image: MRI innovation makes cancerous tissue light up and easier to see (Photo courtesy of Pexels)

A new form of magnetic resonance imaging (MRI) that makes cancerous tissue glow in medical images could help doctors more accurately detect and track the progression of cancer over time.

The innovation, developed by researchers at the University of Waterloo (Ontario, Canada), creates images in which cancerous tissue appears to light up compared to healthy tissue, making it easier to see. Irregular packing of cells leads to differences in the way water molecules move in cancerous tissue compared to healthy tissue. The new technology, called synthetic correlated diffusion imaging, highlights these differences by capturing, synthesizing and mixing MRI signals at different gradient pulse strengths and timings.

In the largest study of its kind, the researchers applied the technology to a cohort of 200 patients with prostate cancer. Compared to standard MRI techniques, synthetic correlated diffusion imaging was better at delineating significant cancerous tissue, making it a potentially powerful tool for doctors and radiologists.

"Our studies show this new technology has promising potential to improve cancer screening, prognosis and treatment planning," said Alexander Wong, Canada Research Chair in Artificial Intelligence and Medical Imaging and a professor of systems design engineering at Waterloo. "Prostate cancer is the second most common cancer in men worldwide and the most frequently diagnosed cancer among men in more developed countries. That's why we targeted it first in our research. We also have very promising results for breast cancer screening, detection, and treatment planning. This could be a game-changer for many kinds of cancer imaging and clinical decision support."

Related Links:
University of Waterloo 

Biopsy Software
Affirm® Contrast
X-Ray Illuminator
X-Ray Viewbox Illuminators
Digital Radiography System
DR-300
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+

Channels

Imaging IT

view channel
Image: Researchers develop a vision-language model trained on large-scale data to generate clinically relevant findings from chest computed tomography images through visual question answering (Ms. Maiko Nagao from Meijo University, Japan)

Interactive AI Tool Supports Explainable Lung Nodule Assessment

Lung cancer is a leading cause of cancer mortality, and timely characterization of pulmonary nodules on chest computed tomography (CT) is essential for directing care. Interpreting nodule morphology demands... Read more

Industry News

view channel
Image: MIM KineticID is 510(k)-pending software for dynamic PET imaging and kinetic modeling, enabling time-based radiotracer analysis for clinical and research decisions (Photo courtesy of GE Healthcare)

GE HealthCare Showcases AI-Enabled Nuclear Medicine Portfolio at SNMMI 2026

Nuclear medicine is expanding rapidly as health systems adopt theranostics and broaden access to radiopharmaceuticals, increasing demand for scalable operations and consistent diagnostic confidence.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.